MedTrace Logo

Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

NCT01053858 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2010-01-22

No results posted yet for this study

Summary

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Conditions

  • Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Interventions

PROCEDURE

intravitreal injection

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Sponsors & Collaborators

  • Hallym University Medical Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-01-31
Completion
2010-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01053858 on ClinicalTrials.gov